Cipla has always been committed As part of the commitment to the treatment and care of cancer patients, Cipla in 1997, established the Cipla Palliative Care and Training Centre in Pune, to provide care to advanced stage cancer patients. In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs – Sorafenib (SORANIB), Gefitinib (GEFTICIP) and Temozolomide (TEMOSIDE).
Following the overwhelming response on the price cut received from the patients and their families and doctors, Cipla is now announcing another breakthrough price reduction in three additional anti-cancer drugs – Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers. The revised prices for the selected products are stated below:
| Indication | Molecule | Brand Name | Current Price (Rs.) | Revised Price (Rs.) | Reduction (Rs.) |
| Lung cancer (metastatic non-small cell cancer) | Erlotinib | ERLOCIP 150 30 tablets |
27,000 | 9,900 | 17,100 |
| ERLOCIP 150 10 tablets |
10,000 | 3,700 | 6,300 | ||
| ERLOCIP 100 30 tablets |
18,000 | 6,600 | 11,400 | ||
| Breast cancer, lung cancer (non-small cell and small cell), head and neck cancer, gastric cancer, bladder cancer | Docetaxel | DOCETAX 20 mg | 3,300 | 1,650 | 1,650 |
| DOCETAX 80 mg | 10,000 | 5,000 | 5,000 | ||
| DOCETAX 120 mg | 14,000 | 7,000 | 7,000 | ||
| Metastatic breast cancer, metastatic colorectal cancer, metastatic colon cancer | Capecitabine | CAPEGARD 500 mg 10 tablets |
1,200 | 600 | 600 |
“Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to now include cancer, not only in India but globally,” announced Dr YK Hamied, Chairman and Managing Director, Cipla.
EP News Bureau